Successful treatment of a case with synchronous follicular lymphoma and gastric adenocarcinoma with CD19 CAR T cells and literature review

J Clin Pharm Ther. 2022 Sep;47(9):1466-1470. doi: 10.1111/jcpt.13666. Epub 2022 Apr 18.

Abstract

What is known and objective: Anti-CD19 CAR-T cell therapy is effective in B-cell lymphoma. However, it is rarely used in lymphoma combined with other malignant tumours.

Case description: A relapsed/refractory follicular lymphoma (r/r FL) patient underwent anti-CD19 CAR-T cell therapy and achieved complete response to lymphoma. However, gastric adenocarcinoma (GAC) was diagnosed during the cellular therapy. After infusion of CAR-T cells, he received curative treatment for GAC, and maitained complete response in both r/r FL and GAC after the treatment.

What is new and conclusion: Anti-CD19 CAR-T therapy is an effective treatment for r/r FL, also provided opportunity for the sequential therapy of GAC, and remained significant quality of life afterwards.

Keywords: CAR T cell therapy; case report; follicular lymphoma; gastric adenocarcinoma; multiple primary malignant tumours.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Adenocarcinoma* / therapy
  • Antigens, CD19
  • Humans
  • Lymphoma, Follicular* / therapy
  • Male
  • Quality of Life
  • Receptors, Chimeric Antigen*
  • Stomach Neoplasms* / therapy
  • T-Lymphocytes

Substances

  • Antigens, CD19
  • Receptors, Chimeric Antigen